首页 | 本学科首页   官方微博 | 高级检索  
     


Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure
Authors:R. Shihmanter MD  I. Nulman MD  S. Goland MD  A. Caspi MD  A. Bar‐Haim PhD  I. Harary PhD  M. Berkovitch MD  L. Arcavi MD
Affiliation:1. Clinical Pharmacology Unit, Kaplan Medical Center, Hebrew University and Hadassah Medical School, , Rehovot, Jerusalem, Israel;2. Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, , Toronto, ON, Canada;3. Department of Cardiology, Kaplan Medical Center, Hebrew University and Hadassah Medical School, , Rehovot, Jerusalem, Israel;4. Biochemistry and Pharmacogenetics Laboratory, Assaf Harofeh Medical Center, , Zerifin, Israel;5. Clinical Pharmacology Unit, Assaf Harofeh Medical Center, , Zerifin, Israel
Abstract:
Keywords:adverse drug reactions  carvedilol     CYP2D6     heart failure
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号